New clinical study links Euromed’s Pomanox® to improved key biomarker of ageing

Mollet del Vallès (Spain), October 2025 – A double-blind, randomised, placebo-controlled clinical trial published in Nutrients reveals that daily supplementation with Pomanox® leads to a statistically significant increase in insulin-like growth factor-1 (IGF-1) in older adults.^[1] IGF-1 supports normal cell growth and repair, and typically declines with age. Pomanox® is a patented, high-polyphenol pomegranate extract produced by botanical ingredients manufacturer Euromed and suitable for cardiovascular, cognitive, metabolic, skin and healthy-ageing applications.

Emerging evidence from cell and animal studies suggests that pomegranate polyphenols may contribute to the attenuation of telomere attrition and the upregulation of insulin-like growth factor 1 (IGF-1). To investigate the effects of pomegranate polyphenols on telomere length and serum IGF-1 levels in humans, 72 adults aged between 55 and 70 completed a 12-week study and received either 740mg/day of Pomanox® or a maltodextrin placebo. Euromed’s Pomanox® is standardised to 30% punicalagins – polyphenols typically found in pomegranates. At the end of the study period, circulating IGF-1 levels showed a small, but significant increase in the pomegranate extract group, with levels remaining largely unchanged in the placebo group. 

Andrea Zangara, Scientific Communication Advisor at Euromed, says: “In older adults, restoring IGF-1 towards mid-physiological levels is associated with better muscle function, metabolic health and vascular integrity, which are all key to longevity and healthy ageing. The modest rise aligns with a physiological ‘sweet spot’, complementing other findings from the same trial, including reductions in selected inflammaging markers, such as IL-6 and IL1β, lower systolic blood pressure and improvements in cognitive flexibility. Together, these results point to a coordinated impact on multiple hallmarks of ageing.”

While these findings are encouraging for product developers, the researchers emphasise the need for confirmation in larger samples and over longer periods, as, for instance, telomere length was not affected in the study. Telomere length is a relatively stable biomarker that typically changes gradually over long periods and possibly even years. Therefore, the 12-week duration of the study may have been insufficient to detect measurable changes. 

The findings of this study suggest that daily supplementation with 740mg of pomegranate extract may elevate IGF-1 levels, indicating its potential to support healthy ageing in older adults, although the broader implications for longevity are still to be confirmed. As the first study to assess the effect of pomegranate extract on telomere length and IGF-1 levels in humans, the researchers noted that it provides important insights into how polyphenol-rich foods and supplements could support healthy ageing. 

^[1] Farhat G, Malla J, Hanson L, Vadher J, Al-Dujaili EAS. Effects of Pomegranate Extract on IGF-1 Levels and Telomere Length in Older Adults (55-70 Years): Findings from a Randomised Double-Blinded Controlled Trial. Nutrients. 2025 Sep 16;17(18):2974. doi: 10.3390/nu17182974.